At a glance
ClinicalIndex Comparison Record- ✓Ischemic discomfort (squeezing, crushing, pressure) substernal or epigastric, or pre-syncopal symptoms with diaphoresis lasting >30 minutes
- ✓ST elevation >0.1 mV in ≥2 contiguous limb leads or >0.2 mV in ≥2 contiguous precordial leads
- ✓Symptom onset <6 hours before enrollment
- ✓Age ≥18 years
- ✕Suspected aortic dissection (chest pain described as ripping/tearing, radiating to back and/or leg, systolic BP difference >15 mmHg between arms)
- ✕Suspected cocaine or amphetamine use within previous 3 days
- ✕Known or suspected pregnancy
- ✕Cardiac arrest requiring intubation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PATCAR Pilot Trial: A Phase 4 Study, Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
In Brief
A Phase 4 clinical trial evaluating Reteplase 10 Units (U) plus a second dose of reteplase 10 U, Reteplase 10 U, and 2 other interventions for Heart Disease and 2 related conditions. Completed, enrolled 390 participants across 1 site.
Detailed Summary
The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates. Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.
Study Details
Timeline
Interventions
Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose
Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose